AR124718A1 - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents

Quinolinas y azaquinolinas como inhibidores de cd38

Info

Publication number
AR124718A1
AR124718A1 ARP220100173A ARP220100173A AR124718A1 AR 124718 A1 AR124718 A1 AR 124718A1 AR P220100173 A ARP220100173 A AR P220100173A AR P220100173 A ARP220100173 A AR P220100173A AR 124718 A1 AR124718 A1 AR 124718A1
Authority
AR
Argentina
Prior art keywords
alkyl
nrc3rd3
membered
nrc3c
haloalkyl
Prior art date
Application number
ARP220100173A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Downing
Kevin Wayne Kuntz
Laurie B Schenkel
Melissa Marie Vasbinder
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of AR124718A1 publication Critical patent/AR124718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP220100173A 2021-01-29 2022-01-28 Quinolinas y azaquinolinas como inhibidores de cd38 AR124718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
AR124718A1 true AR124718A1 (es) 2023-04-26

Family

ID=80446310

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100173A AR124718A1 (es) 2021-01-29 2022-01-28 Quinolinas y azaquinolinas como inhibidores de cd38

Country Status (25)

Country Link
US (2) US11952377B2 (cg-RX-API-DMAC7.html)
EP (2) EP4674415A3 (cg-RX-API-DMAC7.html)
JP (2) JP7777596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230141799A (cg-RX-API-DMAC7.html)
CN (1) CN117580829A (cg-RX-API-DMAC7.html)
AR (1) AR124718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022212035A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208851A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009803A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230323A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000142A (cg-RX-API-DMAC7.html)
EC (1) ECSP23056223A (cg-RX-API-DMAC7.html)
ES (1) ES3042412T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251111T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072981T2 (cg-RX-API-DMAC7.html)
IL (1) IL304466A (cg-RX-API-DMAC7.html)
JO (1) JOP20230160A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008701A (cg-RX-API-DMAC7.html)
PE (1) PE20232047A1 (cg-RX-API-DMAC7.html)
PL (1) PL4284511T3 (cg-RX-API-DMAC7.html)
RS (1) RS67253B1 (cg-RX-API-DMAC7.html)
TW (1) TW202241418A (cg-RX-API-DMAC7.html)
WO (1) WO2022165114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
CN117715897A (zh) 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors
WO2026143049A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Aminoquinolinones useful as cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
CN107428733A (zh) 2014-12-03 2017-12-01 葛兰素史克知识产权第二有限公司 Cd38抑制剂和治疗方法
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제

Also Published As

Publication number Publication date
JP2025160175A (ja) 2025-10-22
TW202241418A (zh) 2022-11-01
ECSP23056223A (es) 2023-11-30
EP4674415A3 (en) 2026-03-04
CL2023002163A1 (es) 2024-01-05
PE20232047A1 (es) 2023-12-27
CA3208851A1 (en) 2022-08-04
JP2024506814A (ja) 2024-02-15
JOP20230160A1 (ar) 2023-07-20
US11952377B2 (en) 2024-04-09
EP4284511A1 (en) 2023-12-06
IL304466A (en) 2023-09-01
HUE072981T2 (hu) 2025-12-28
EP4674415A2 (en) 2026-01-07
US20240279224A1 (en) 2024-08-22
PL4284511T3 (pl) 2025-12-22
JP7777596B2 (ja) 2025-11-28
AU2022212035A1 (en) 2023-08-03
ES3042412T3 (en) 2025-11-20
RS67253B1 (sr) 2025-10-31
WO2022165114A1 (en) 2022-08-04
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
KR20230141799A (ko) 2023-10-10
EP4284511B1 (en) 2025-07-16
HRP20251111T1 (hr) 2025-11-21
CN117580829A (zh) 2024-02-20
MX2023008701A (es) 2023-11-29
DOP2023000142A (es) 2023-08-31
CO2023009803A2 (es) 2023-10-09
CL2024001535A1 (es) 2024-11-04
US20220242862A1 (en) 2022-08-04
EP4284511C0 (en) 2025-07-16
CR20230323A (es) 2023-10-02

Similar Documents

Publication Publication Date Title
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR121419A1 (es) Piridazinonas como inhibidoras de parp7
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR113965A1 (es) Triazol azoles ciclohexil ácidos como antagonistas de lpa
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR109658A1 (es) Inhibidores de la interacción de menina-mll
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
AR082681A1 (es) Inhibidores del virus de la hepatitis c
GEAP202115066A (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR105648A1 (es) Métodos para la preparación de ácidos biliares y derivados de los mismos
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
JP2015520769A5 (cg-RX-API-DMAC7.html)
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR108778A1 (es) Compuestos antibacterianos
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco